MeSH term
Frequency | Condition_Probility | Adult | 6 | 0.0 |
Aged | 5 | 0.0 |
Aged, 80 and over | 3 | 0.0 |
Animals | 12 | 0.0 |
Blotting, Western | 2 | 0.0 |
Female | 11 | 0.0 |
Humans | 27 | 0.0 |
Male | 12 | 0.0 |
Mice | 11 | 0.0 |
Mice, Nude | 5 | 0.0 |
Middle Aged | 6 | 0.0 |
RNA, Messenger/metabolism | 2 | 0.0 |
Receptors, Bombesin/genetics/*metabolism | 3 | 50.0 |
Research Support, U.S. Gov't, P.H.S. | 17 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 5 | 0.0 |
Survival Analysis | 2 | 0.0 |
Time Factors | 2 | 0.0 |
Tumor Cells, Cultured | 9 | 0.0 |
Bombesin/pharmacology | 2 | 13.0 |
Cloning, Molecular | 3 | 0.0 |
Gene Expression Regulation | 2 | 0.0 |
Receptors, Bombesin/*metabolism | 6 | 46.0 |
Research Support, Non-U.S. Gov't | 19 | 0.0 |
Comparative Study | 4 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 10 | 0.0 |
Tissue Distribution | 7 | 0.0 |
Tumor Markers, Biological/*metabolism | 2 | 0.0 |
Bombesin/metabolism | 2 | 28.0 |
Radioligand Assay | 2 | 0.0 |
Binding, Competitive | 2 | 0.0 |
Gene Expression | 4 | 0.0 |
Polymorphism, Genetic | 2 | 0.0 |
Adenoviridae/*genetics | 2 | 0.0 |
Genetic Vectors | 3 | 0.0 |
Immunohistochemistry | 4 | 0.0 |
Neoplasm Staging | 2 | 0.0 |
Amino Acid Sequence | 2 | 0.0 |
Base Sequence | 9 | 0.0 |
*Chromosome Mapping | 3 | 0.0 |
In Situ Hybridization, Fluorescence | 2 | 0.0 |
Introns | 2 | 0.0 |
Molecular Sequence Data | 7 | 0.0 |
Receptors, Bombesin/*genetics | 4 | 57.0 |
Transcription, Genetic | 2 | 0.0 |
Mice, Inbred BALB C | 2 | 0.0 |
Exons | 2 | 0.0 |
Restriction Mapping | 2 | 0.0 |
*X Chromosome | 4 | 0.0 |
Bombesin/analogs & derivatives/*diagnostic use/pharmacokinetics | 2 | 100.0 |
Abnormalities, Multiple/*genetics | 2 | 0.0 |
Syndrome | 2 | 0.0 |
DNA Mutational Analysis | 2 | 0.0 |
Receptors, Bombesin/metabolism | 2 | 28.0 |
DNA Primers | 2 | 0.0 |
Genetic Markers | 2 | 0.0 |
Repetitive Sequences, Nucleic Acid | 2 | 0.0 |
Polymerase Chain Reaction | 2 | 0.0 |
